CA2420032A1 - Oral delivery of peptide - Google Patents

Oral delivery of peptide Download PDF

Info

Publication number
CA2420032A1
CA2420032A1 CA002420032A CA2420032A CA2420032A1 CA 2420032 A1 CA2420032 A1 CA 2420032A1 CA 002420032 A CA002420032 A CA 002420032A CA 2420032 A CA2420032 A CA 2420032A CA 2420032 A1 CA2420032 A1 CA 2420032A1
Authority
CA
Canada
Prior art keywords
proliposome
drug
water
preparation
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002420032A
Other languages
English (en)
French (fr)
Inventor
Hack-Joo Kim
Heung-Man An
Min-Jong Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2420032A1 publication Critical patent/CA2420032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002420032A 2000-08-11 2000-08-11 Oral delivery of peptide Abandoned CA2420032A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/000892 WO2002013782A1 (en) 2000-08-11 2000-08-11 Oral delivery of peptide

Publications (1)

Publication Number Publication Date
CA2420032A1 true CA2420032A1 (en) 2002-02-21

Family

ID=19198254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002420032A Abandoned CA2420032A1 (en) 2000-08-11 2000-08-11 Oral delivery of peptide

Country Status (6)

Country Link
EP (1) EP1311239A4 (de)
JP (1) JP2004506003A (de)
CN (1) CN1479609A (de)
AU (1) AU2000264796A1 (de)
CA (1) CA2420032A1 (de)
WO (1) WO2002013782A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010801A (zh) * 2021-11-16 2022-02-08 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963A (zh) * 2021-11-16 2022-02-25 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
AU2003210477A1 (en) 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
CN100371018C (zh) * 2003-06-12 2008-02-27 刘青松 降钙素组合物
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
JP2008179563A (ja) * 2007-01-24 2008-08-07 Cosmo Shokuhin Kk 有用リン脂質組成物を含む機能性素材及び機能性食品
WO2009149537A1 (en) * 2008-06-12 2009-12-17 Christine Allen Injectable polymer-lipid blend
RU2015144851A (ru) 2009-06-18 2019-01-10 Серенити Фармасьютикалз, Элэлси Безопасное применение десмопрессина
CN103127003B (zh) * 2013-03-19 2014-05-07 广东彼迪药业有限公司 一种奥美拉唑肠溶微丸、胶囊及其制备方法
CN105902400B (zh) * 2016-06-17 2019-10-11 四川百奥可生物科技有限责任公司 一种包裹生物酶的微粒及其制备方法和应用
CN107952063A (zh) * 2017-12-27 2018-04-24 北京四环生物制药有限公司 降钙素片及其制备方法
CN116407621A (zh) * 2021-12-30 2023-07-11 武汉虹辰远荣生物制品有限公司 一种能辅助预防老年痴呆症的纳豆产品

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0143949B1 (de) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
ES2130056B1 (es) * 1997-01-16 2000-02-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010801A (zh) * 2021-11-16 2022-02-08 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963A (zh) * 2021-11-16 2022-02-25 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用
CN114010801B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用

Also Published As

Publication number Publication date
CN1479609A (zh) 2004-03-03
AU2000264796A1 (en) 2002-02-25
JP2004506003A (ja) 2004-02-26
EP1311239A1 (de) 2003-05-21
EP1311239A4 (de) 2005-06-22
WO2002013782A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
CA2420032A1 (en) Oral delivery of peptide
DE60038097T2 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
RU1837869C (ru) Способ получени дисперсии полипептидов дл интраназольного применени
DE60307082T4 (de) In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
US6824790B2 (en) Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
JP2015155433A (ja) ペプチドの組成物及びその調製方法
CA3113240C (en) Transmucosal psychoactive alkaloid composition and preparation thereof
JP2016538339A (ja) プロ酵素及び酵素の混合物を含む医薬組成物
CN108635375A (zh) 预防或治疗肝病和肝纤维化及改善肝功能的熊胆粉及用途
CN110464835A (zh) 一种胰岛素柔性微粒及其制剂
CN103877011A (zh) 一种细辛脑注射剂及制备方法
WO2003099261A1 (en) Liposome drug delivery
KR20030064742A (ko) 펩타이드성 약물의 경구용 제제
KR20120138908A (ko) 엔테카비르를 함유하는 미립구 및 이의 제조방법
CN105169409A (zh) 普萘洛尔或其可药用盐与离子交换树脂的复合物及其混悬液
CN112494452B (zh) 一种水飞蓟宾胶囊及其制备方法
EP4049670A1 (de) Verfahren zur herstellung eines urolithin-angereicherten trockenextrakts und verwandter zusätze mit antioxidativen und entzündungshemmenden wirkungen auf systemischer ebene
RU2314103C1 (ru) Раствор моксифлоксацина для инъекций и способ его получения
KR20260054762A (ko) 데커시놀을 이용한 경구용해필름 제제 및 그의 제조방법
Kadhim et al. PREPARATION AND CHARACTERIZATION OF EZETIMIBE FREEZE-DRIED TABLETS USING ZYDIS® TECHNOLOGY
HK1063286A1 (en) Powdery preparations and proecess for producing the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead